Cancer-Causing Mutations in a Novel Transcription-Dependent Nuclear Export Motif of VHL Abrogate Oxygen-Dependent Degradation of Hypoxia-Inducible Factor

REFERENCES

• Afonina, E., R. Stauber, and G. N. Pavlakis. 1998. The human poly(A)-binding protein 1 shuttles between the nucleus and the cytoplasm. J. Biol. Chem. 273:13015–13021.
   PubMed Web of Science ®Google Scholar
• Blondel, M., J. M. Galan, Y. Chi, C. Lafourcade, C. Longaretti, R. J. Deshaies, and M. Peter. 2000. Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4. EMBO J. 19:6085–6097.
   PubMed Web of Science ®Google Scholar
• Bogerd, H. P., R. A. Fridell, R. E. Benson, J. Hua, and B. R. Cullen. 1996. Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay. Mol. Cell. Biol. 16:4207–4214.
   PubMed Web of Science ®Google Scholar
• Bonicalzi, M. E., I. Groulx, N. de Paulsen, and S. Lee. 2001. Role of exon 2-encoded beta-domain of the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 276:1407–1416.
   PubMedGoogle Scholar
• Bruick, R. K., and S. L. McKnight. 2001. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294:1337–1340.
   PubMed Web of Science ®Google Scholar
• Chen, F., T. Kishida, M. Yao, T. Hustad, D. Glavac, M. Dean, J. R. Gnarra, M. L. Orcutt, F. M. Duh, G. Glenn, et al. 1995. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5:66–75.
   PubMed Web of Science ®Google Scholar
• Cockman, M. E., N. Masson, D. R. Mole, P. Jaakkola, G. W. Chang, S. C. Clifford, E. R. Maher, C. W. Pugh, P. J. Ratcliffe, and P. H. Maxwell. 2000. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275:25733–25741.
   PubMed Web of Science ®Google Scholar
• Epstein, A. C., J. M. Gleadle, L. A. McNeill, K. S. Hewitson, J. O'Rourke, D. R. Mole, M. Mukherji, E. Metzen, M. I. Wilson, A. Dhanda, Y. M. Tian, N. Masson, D. L. Hamilton, P. Jaakkola, R. Barstead, J. Hodgkin, P. H. Maxwell, C. W. Pugh, C. J. Schofield, and P. J. Ratcliffe. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43–54.
   PubMed Web of Science ®Google Scholar
• Fischer, U., J. Huber, W. C. Boelens, I. W. Mattaj, and R. Luhrmann. 1995. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82:475–483.
   PubMed Web of Science ®Google Scholar
• Fornerod, M., M. Ohno, M. Yoshida, and I. W. Mattaj. 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90:1051–1060.
   PubMed Web of Science ®Google Scholar
• Franovic, A., I. Robert, K. Smith, G. Kurban, A. Pause, L. Gunaratnam, and S. Lee. 2006. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res. 66:8083–8090.
   PubMedGoogle Scholar
• Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:7288–7293.
   PubMed Web of Science ®Google Scholar
• Fukuchi, M., T. Imamura, T. Chiba, T. Ebisawa, M. Kawabata, K. Tanaka, and K. Miyazono. 2001. Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Mol. Biol. Cell 12:1431–1443.
   PubMed Web of Science ®Google Scholar
• Fukuda, M., S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, and E. Nishida. 1997. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390:308–311.
   PubMed Web of Science ®Google Scholar
• Gallou, C., D. Chauveau, S. Richard, D. Joly, S. Giraud, S. Olschwang, N. Martin, C. Saquet, Y. Chretien, A. Mejean, J. M. Correas, G. Benoit, P. Colombeau, J. P. Grunfeld, C. Junien, and C. Beroud. 2004. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum. Mutat. 24:215–224.
   PubMed Web of Science ®Google Scholar
• Groulx, I., M. E. Bonicalzi, and S. Lee. 2000. Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2. J. Biol. Chem. 275:8991–9000.
   PubMed Web of Science ®Google Scholar
• Groulx, I., and S. Lee. 2002. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 22:5319–5336.
   PubMedGoogle Scholar
• Gunaratnam, L., M. Morley, A. Franovic, N. de Paulsen, K. Mekhail, D. A. Parolin, E. Nakamura, I. A. Lorimer, and S. Lee. 2003. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 278:44966–44974.
   PubMed Web of Science ®Google Scholar
• Hansen, W. J., M. Ohh, J. Moslehi, K. Kondo, W. G. Kaelin, and W. J. Welch. 2002. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol. Cell. Biol. 22:1947–1960.
   PubMed Web of Science ®Google Scholar
• Harris, A. L. 2002. Hypoxia: a key regulatory factor in tumour growth. Nat. Rev. Cancer 2:38–47.
   PubMed Web of Science ®Google Scholar
• Henderson, B. R., and A. Eleftheriou. 2000. A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. Exp. Cell. Res. 256:213–224.
   PubMed Web of Science ®Google Scholar
• Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67:425–479.
   PubMed Web of Science ®Google Scholar
• Ivan, M., and W. G. Kaelin, Jr. 2001. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. 11:27–34.
   PubMed Web of Science ®Google Scholar
• Ivan, M., K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J. M. Asara, W. S. Lane, and W. G. Kaelin, Jr. 2001. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464–468.
   PubMed Web of Science ®Google Scholar
• Iwai, K., K. Yamanaka, T. Kamura, N. Minato, R. C. Conaway, J. W. Conaway, R. D. Klausner, and A. Pause. 1999. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. USA 96:12436–12441.
   PubMed Web of Science ®Google Scholar
• Jaakkola, P., D. R. Mole, Y. M. Tian, M. I. Wilson, J. Gielbert, S. J. Gaskell, A. Kriegsheim, H. F. Hebestreit, M. Mukherji, C. J. Schofield, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe. 2001. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468–472.
   PubMed Web of Science ®Google Scholar
• Kaelin, W. G., Jr. 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2:673–682.
   PubMed Web of Science ®Google Scholar
• Kaelin, W. G., Jr., and E. R. Maher. 1998. The VHL tumour-suppressor gene paradigm. Trends Genet. 14:423–426.
   PubMed Web of Science ®Google Scholar
• Kalderon, D., B. L. Roberts, W. D. Richardson, and A. E. Smith. 1984. A short amino acid sequence able to specify nuclear location. Cell 39:499–509.
   PubMed Web of Science ®Google Scholar
• Kibel, A., O. Iliopoulos, J. A. DeCaprio, and W. G. Kaelin, Jr. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269:1444–1446.
   PubMed Web of Science ®Google Scholar
• Kudo, N., N. Matsumori, H. Taoka, D. Fujiwara, E. P. Schreiner, B. Wolff, M. Yoshida, and S. Horinouchi. 1999. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. USA 96:9112–9117.
   PubMed Web of Science ®Google Scholar
• Kutay, U., and S. Guttinger. 2005. Leucine-rich nuclear-export signals: born to be weak. Trends Cell. Biol. 15:121–124.
   PubMed Web of Science ®Google Scholar
• Latif, F., K. Tory, J. Gnarra, M. Yao, F. M. Duh, M. L. Orcutt, T. Stackhouse, I. Kuzmin, W. Modi, L. Geil, et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317–1320.
   PubMed Web of Science ®Google Scholar
• Lee, S., M. Neumann, R. Stearman, R. Stauber, A. Pause, G. N. Pavlakis, and R. D. Klausner. 1999. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 19:1486–1497.
   PubMed Web of Science ®Google Scholar
• Leroux, M. R., and F. U. Hartl. 2000. Protein folding: versatility of the cytosolic chaperonin TRiC/CCT. Curr. Biol. 10:R260–R264.
   PubMedGoogle Scholar
• Li, L., L. Zhang, X. Zhang, Q. Yan, Y. A. Minamishima, A. F. Olumi, M. Mao, S. Bartz, and W. G. Kaelin, Jr. 2007. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2a and type 2b Vhl mutations. Mol. Cell. Biol. 27:5381–5392.
   PubMed Web of Science ®Google Scholar
• Lindstrom, M. S., A. Jin, C. Deisenroth, G. White Wolf, and Y. Zhang. 2007. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol. Cell. Biol. 27:1056–1068.
   PubMed Web of Science ®Google Scholar
• Lisztwan, J., G. Imbert, C. Wirbelauer, M. Gstaiger, and W. Krek. 1999. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13:1822–1833.
   PubMed Web of Science ®Google Scholar
• Lonergan, K. M., O. Iliopoulos, M. Ohh, T. Kamura, R. C. Conaway, J. W. Conaway, and W. G. Kaelin, Jr. 1998. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18:732–741.
   PubMed Web of Science ®Google Scholar
• Maher, E. R., and W. G. Kaelin, Jr. 1997. von Hippel-Lindau disease. Medicine (Baltimore) 76:381–391.
   PubMed Web of Science ®Google Scholar
• Maxwell, P. H., M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275.
   PubMed Web of Science ®Google Scholar
• Mekhail, K., L. Gunaratnam, M. E. Bonicalzi, and S. Lee. 2004. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat. Cell Biol. 6:642–647.
   PubMed Web of Science ®Google Scholar
• Mekhail, K., M. Khacho, A. Carrigan, R. R. Hache, L. Gunaratnam, and S. Lee. 2005. Regulation of ubiquitin ligase dynamics by the nucleolus. J. Cell Biol. 170:733–744.
   PubMed Web of Science ®Google Scholar
• Mekhail, K., M. Khacho, L. Gunaratnam, and S. Lee. 2004. Oxygen sensing by H+: implications for HIF and hypoxic cell memory. Cell Cycle 3:1027–1029.
   PubMed Web of Science ®Google Scholar
• Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245.
   PubMed Web of Science ®Google Scholar
• Ohh, M., C. W. Park, M. Ivan, M. A. Hoffman, T.-Y. Kim, L. E. Huang, N. Pavletich, V. Chau, and W. G. Kaelin. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the [bgr]-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2:423–427.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857–860.
   PubMed Web of Science ®Google Scholar
• Pastore, Y., K. Jedlickova, Y. Guan, E. Liu, J. Fahner, H. Hasle, J. F. Prchal, and J. T. Prchal. 2003. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am. J. Hum. Genet. 73:412–419.
   PubMed Web of Science ®Google Scholar
• Pastore, Y. D., J. Jelinek, S. Ang, Y. Guan, E. Liu, K. Jedlickova, L. Krishnamurti, and J. T. Prchal. 2003. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 101:1591–1595.
   PubMed Web of Science ®Google Scholar
• Pause, A., S. Lee, R. A. Worrell, D. Y. Chen, W. H. Burgess, W. M. Linehan, and R. D. Klausner. 1997. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA 94:2156–2161.
   PubMed Web of Science ®Google Scholar
• Phair, R. D., and T. Misteli. 2000. High mobility of proteins in the mammalian cell nucleus. Nature 404:604–609.
   PubMed Web of Science ®Google Scholar
• Rasmussen, A., S. Nava-Salazar, P. Yescas, E. Alonso, R. Revuelta, I. Ortiz, S. Canizales-Quinteros, M. T. Tusie-Luna, and M. Lopez-Lopez. 2006. Von Hippel-Lindau disease germline mutations in Mexican patients with cerebellar hemangioblastoma. J. Neurosurg. 104:389–394.
   PubMedGoogle Scholar
• Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:554–564.
   PubMed Web of Science ®Google Scholar
• Scheffner, M. 1999. Moving protein heads for breakdown. Nature 398:103–104.
   PubMed Web of Science ®Google Scholar
• Semenza, G. L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3:721–732.
   PubMed Web of Science ®Google Scholar
• Smith, K., L. Gunaratnam, M. Morley, A. Franovic, K. Mekhail, and S. Lee. 2005. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res. 65:5221–5230.
   PubMed Web of Science ®Google Scholar
• Stade, K., C. S. Ford, C. Guthrie, and K. Weis. 1997. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 90:1041–1050.
   PubMed Web of Science ®Google Scholar
• Tomoda, K., Y. Kubota, and J. Kato. 1999. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398:160–165.
   PubMed Web of Science ®Google Scholar
• Weissman, A. M. 2001. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2:169–178.
   PubMed Web of Science ®Google Scholar
• Wen, W., J. L. Meinkoth, R. Y. Tsien, and S. S. Taylor. 1995. Identification of a signal for rapid export of proteins from the nucleus. Cell 82:463–473.
   PubMed Web of Science ®Google Scholar
• Whaley, J. M., J. Naglich, L. Gelbert, Y. E. Hsia, J. M. Lamiell, J. S. Green, D. Collins, H. P. Neumann, J. Laidlaw, F. P. Li, et al. 1994. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am. J. Hum. Genet. 55:1092–1102.
   PubMed Web of Science ®Google Scholar
• Yu, F., S. B. White, Q. Zhao, and F. S. Lee. 2001. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 98:9630–9635.
   PubMed Web of Science ®Google Scholar